Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Current Liabilities (2016 - 2026)

United Therapeutics' Total Current Liabilities history spans 17 years, with the latest figure at $560.6 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 24.05% to $560.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $560.6 million, a 24.05% decrease, with the full-year FY2025 number at $560.6 million, down 24.05% from a year prior.
  • Total Current Liabilities hit $560.6 million in Q4 2025 for United Therapeutics, up from $546.3 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for UTHR hit a ceiling of $873.4 million in Q3 2024 and a floor of $292.6 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $521.3 million across 5 years, with a median of $448.7 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: surged 165.13% in 2024 and later plummeted 37.45% in 2025.
  • Tracing UTHR's Total Current Liabilities over 5 years: stood at $305.4 million in 2021, then increased by 12.38% to $343.2 million in 2022, then skyrocketed by 134.38% to $804.4 million in 2023, then dropped by 8.24% to $738.1 million in 2024, then dropped by 24.05% to $560.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for UTHR at $560.6 million in Q4 2025, $546.3 million in Q3 2025, and $527.1 million in Q2 2025.